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Abstract Nodular lymphocyte predominant Hodgkin lym-
phoma (NLPHL) is a subtype of Hodgkin lymphoma charac-
terized by a unique clinical and histological presentation. Be-
cause of the rare nature of this disease, few large-scale studies
are available. We conducted a cohort study in which patients
were identified in the Netherlands Cancer Registry in the
Southeast of the Netherlands between 1990 and 2010. Of
these patients, we collected all clinical characteristics and re-
reviewed pathologic material to confirm NLPHL diagnosis.
Seventy-three histologically confirmed cases of NLPHL were
analyzed with a median follow-up of 65 months (range 4–
257 months). Median age at diagnosis was 43 years (range
1–87); 84.9 % of the patients were male; B symptoms were
present in 5.5 %; and stage I/II disease was most common
(75.4 %). Patients were primarily treated with radiotherapy
(50.7 %), chemotherapy (26 %), combined modality (radio-
therapy and chemotherapy) (11 %), or surgical excision with
careful watch-and-wait (12.3 %). Relapses occurred in seven
patients (9.6 %) after a median of 26 months (21–74 months).
Six patients (8.2 %) developed histologic transformation to
large cell lymphoma. Five patients (6.8 %) died during
follow-up due to progression of NLPHL (n=1), histologic
transformation (n=2) and intercurrent deaths (n=2). The es-
timated 10-year overall survival was 94.0 % and the 10-year
progression-free survival 75.8 %. Our study confirms the dis-
tinct characteristics of NLPHL with a relatively good long-
term prognosis. It may be possible to reduce treatment inten-
sity in early stage NLPHL without affecting long-term
outcome.
Keywords Chemotherapy . Epidemiology . Nodular
lymphocyte predominant Hodgkin lymphoma . Outcome .
Radiotherapy
Introduction
Nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is a rare subtype of Hodgkin lymphoma (HL) that
accounts for approximately 5 % of all cases of HL [1]. It is
distinguished from classical Hodgkin lymphoma (cHL) by
clinical, histological, and immunophenotypic characteristics.
Histologically, NLPHL is marked by the presence of lympho-
cyte predominant (LP) cells [2], previously known as lympho-
cytic and histiocytic (L and H) or Bpopcorn^ cells, embedded
in nodules consisting of B cells and other reactive cells (main-
ly reactive Tcells) [3]. In contrast to cHL, Reed-Sternberg and
Hodgkin (RSH) cells are rarely seen in NLPHL, and immu-
nohistochemistry shows a different pattern on the malignant
cells; RSH cells typically express CD15 and CD30, whereas
LP cells lack expression of these markers, but express B cell
markers like CD20, CD22, and CD79a and also express the
common leukocyte antigen CD45, which is uncommon on
RSH cells [4].
NLPHL was first recognized as a distinct disease entity in
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classification of 1994, while beforehand NLPHL, was classi-
fied as cHL [5]. Hence, studies published before 1994 are
often less representative for analysis of clinical presentation,
treatment, and outcome. Furthermore, re-review of patient
material on both morphological and immunohistochemical
characteristics by an expert hematopathologist to confirm
NLPHL is needed, as one study showed that only 51 % of
originally diagnosed NLPHL cases was confirmed [1]. Be-
cause of the rare nature of this disease, few large-scale studies
are available.
In comparisonwith cHL, NLPHL presents more often in an
early stage of disease and has a male predominance (75 %) [1,
6–8]. In NLPHL, BB^ symptoms are uncommon, as is bulky
disease or involvement of mediastinal, abdominal, and
extranodal sites [9]. The ideal treatment of NLPHL has not
yet been established. Mostly, radiotherapy is used in case of
limited disease (stage I and II), and combination therapy (che-
motherapy and radiotherapy) is used in advanced-stage dis-
ease (like in cHL) [10]. Rituximab, an anti-CD20 antibody, is
a promising therapy, but given the paucity of data, it is not yet
considered first-line treatment of choice [11–13]. It is being
increasingly recognized that late toxicities of treatment, like
secondary malignancies and cardiovascular disease, can pose
significant health problems and therefore treatment should be
as limited as possible to prevent these late toxicities [14].
Furthermore, despite the good prognosis of NLPHL, recur-
rences are common, and there is a risk (of up to 13 %) of
histologic transformation to non-Hodgkin lymphoma, typical-
ly diffuse large B cell lymphoma (DLBCL) [15].
The purpose of this study was to examine the epidemiolo-
gy, clinical features, treatment, and outcome of patients with
NLPHL, derived from the population-based cancer registry in
the Southeast of the Netherlands, to get more insight in this
rare subtype of Hodgkin lymphoma. Furthermore, we wanted
to examine the percentage of discordant diagnoses through a
central review of the histological material by expert lympho-
ma pathologists of our university hospital.
Methods
All patients diagnosed with NLPHL in the Southeastern part
of the Netherlands between 1990 and 2010 were identified
through the Netherlands Cancer Registry (NCR). This region
comprised 17 general hospitals and 1 university hospital. For
all cases, histological material of the tumor was requested
from the pathology labs and reviewed by an expert
hematopathologist.
Standard data concerning patient and tumor characteristics
were retrieved from the NCR. Retrospectively, additional data
was collected by one researcher (I.D.) by consulting medical
files using a standardized registration form. The following
data were recorded: sex, age at time of diagnosis, presence
or absence of B symptoms, Ann Arbor stage, presence of
bulky mediastinal mass (tumor mass ≥10 cm; >0,35
mediastinum/thorax (MT) ratio), presence and number of in-
volved lymph nodes, involvement of extranodal sites, the
presence of European Organization for Research and Treat-
ment of Cancer (EORTC) risk factors for stage I/II unfavor-
able risk disease [16], Hasenclever international prognostic
score (IPS) for advanced-stage disease [17], presence of ele-
vated lactate dehydrogenase (LDH), treatment, complications
of treatment, date of recurrence, treatment of recurrence, his-
tologic transformation, and date and cause of death.
Overall survival (OS) was defined as the time from date of
diagnosis until the last date of follow-up or death, whichever
came first. Progression-free survival (PFS) was measured
from the date of diagnosis to the date of progression, transfor-
mation, or death from any cause, whichever occurred first.
Early stage disease was defined as clinical stage I and II.
Advanced-stage disease was defined as clinical stage III or IV.
Data were analyzed using Prism GraphPad software, ver-
sion 5.0 (GraphPad Software, La Jolla, CA, USA). Standard
descriptive statistical analyses were performed. Survival anal-
ysis was performed using the Kaplan-Meier method and pre-
sented as survival curves. Two-tailed P values <0.05 were
considered statistically significant.
Results
We identified 83 patients of whom three patients were exclud-
ed from further analysis because of unavailability of identifi-
cation data. After pathology review, seven patients (8.8 %)
were excluded because of discordant diagnosis; five patients
were reclassified as cHL; and for two patients no conclusive
diagnosis could be made. Thus, a total of 73 patients were
included in the final analysis. The median follow-up time
was 65 months (range 4–257 months).
The incidence of NLPHL increased during the study period
from 6 new patients from 1990-1995 to 9 patients from 1996–
2000, 20 patients from 2001–2005, and 38 patients in the most
recent period (2006–2010). The incidence of NLPHL in-
creased from 0.09 per 100,000 person years in 1990 to 0.30
per 100,000 person years in 2010, while the incidence of HL
altogether remained stable during those years with an inci-
dence of 2.31 per 100,000 person years in 1990 and 2.40 per
100,000 person years in 2010.
The main patient characteristics in comparison with recent
studies are shown in Table 1. The median age of the patients
was 43 years (range 1–87), and the majority of patients were
male. We included eight children and they were diagnosed at
the age of 1, 5, 9 (2), 12 (2), 14, and 15 years.
Early stage NLPHL was present in 75.4 % of the patients.
B symptoms at the time of presentation were present in only
5.5 % of patients. In 55 patients with early stage disease, only
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nine had an unfavorable risk profile, and age was the only
EORTC prognostic adverse risk factor for these patients. Pa-
tients with advanced disease scored at least 1 point in the
Hasenclever score (median score of 2), with higher age and
male sex as the most common risk factors.
One patient with stage II disease had extranodal disease of
Waldeyers ring. None of the patients with stage III disease
showed extranodal disease, but one patient had splenic in-
volvement. In stage IV disease, splenic involvement was pres-
ent in four of five patients, and four patients had skeletal
involvement. Also, the thyroid gland, bone marrow, or liver
was involved in one patient each.
Nine patients (12.3 %) had elevated LDH levels. Two of
these patients died; three patients had a relapse; and four were
cured without a relapse.
With regard to treatment, four different treatment options
were used; a careful watch-and-wait strategy (after surgical
excision of the only involved lymph node), involved-field
radiotherapy, chemotherapy, or combined modality treatment
(chemotherapy and radiotherapy). The different treatment
modalities for different stages are shown in Table 2. Radio-
therapy was the most used treatment option. Watch-and-wait
was only used in nine patients with early stage disease; one of
these nine patients refused treatment; one patient also had
colorectal cancer for which treatment was given priority; five
patients had long lasting lymphadenopathy (one patient al-
ready for 15 years); and two patients were children of 9 and
14 years old. Chemotherapy alone was mainly used in the
advanced-stage group. Combined treatment modality was
used in 11 % of the patients. Chemotherapy consisted of
ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
for a mean of 6 cycles (range 2–8) in eight patients, or
MOPP-ABV (mechlorethamine, vincristine, procarbazine,
prednisone-doxorubicin, bleomycin, vincristine) in six pa-
tients with a mean of 6 cycles (range 3–8). The combination
of rituximab, cyclophosphamide, adriamycin, vincristine, and
prednisone (R-CHOP) was used in four patients with a mean
of 8 cycles, all in patients with localization in the spleen and/or
stage IV disease, mainly because the advanced-stage presen-
tation raised doubt on the representativity of the biopsied
Table 1 Clinical characteristics of NLPHL patients in the current and recent studies
Characteristic Our cohort Farrell, 2011 [9] Chen, 2010a [20] Biasoli, 2010 [18] Al-Mansour, 2010 [15]
No. of patients 73 69 113 164 95
Follow-up (months; median and range) 65 (4–257) 53 (11–165) 136 (0–421) 114 78 (30–369)
Discordant diagnosisb (%) 8.8 2.8 0 15.9 20
Male (number, %) 62 (85 %) 48 (70 %) 93 (82 %) 131 (80 %) 69 (73 %)
Age (median and range) 43 (1–87) 39 (11–79) 27 (3–77) 30 (8–69) 37 (15–77)
Stage (number, %)
I 31 (43 %) 35 (51 %) 71 (63 %) 97 (60 %) 64 (67 %)e
II 24 (33 %) 21 (30 %) 42 (37 %) 60 (36 %) –
III 12 (16 %) 9 (13 %) 0 6 (4 %) 31 (33 %)f
IV 5 (7 %) 4 (6 %) 0 0 –
Early stage disease 55 (75 %) 56 (81 %) 113 (100 %) 157 (96 %) 64 (67 %)
B symptomsc (number, %) 4 (5.5 %) 3 (4.3 %) 0 7 (4.3 %) 8 (8.4 %)
Treatment modality (number, %)
Watch-and-wait 31 (43 %) 5 (7 %) 0 58 (35 %) 2 (2 %)
Radiotherapy 37 (51 %) 37 (54 %) 93 (82 %) 43 (27 %) 26 (27 %)
Chemotherapy 19 (26 %) 15 (22 %) 7 (6 %) 15 (9 %) 31 (33 %)
Combine modality 8 (11 %) 12 (17 %) 13 (12 %) 48 (29 %) 33 (35 %)
Not specified – – – – 3 (3 %)
Deathsd (number, %) 5 (6.8 %) 0 13 (11.5 %) 14 (8.5 %) 16 (16.8 %)
Transformation 6 (8.2 %) 2 (2.9 %) NS 19 (11.2 %) 13 (14 %)
NS not specified
a This study only included early stage
b Percentage of excluded patients with a discordant diagnosis from the total number of patients that were reviewed
c B symptoms: fever, weight loss >10 % of body weight in 6 months and/or night sweats
d Deaths from all causes, not NLPHL-specific
e Stage I and II together
f Stage III and IV together
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tissue for the diagnosis of NLPHL and the clinical suspicion
of concordant presence of DLBCL. Other regimens included
MOPP (in one patient, 6 cycles); vincristine, etoposide,
doxorubicine, and prednisone (OEPA, in three pediatric pa-
tients, all 2 cycles); and cyclophosphamide, vincristine, pred-
nisone (CVP) with rituximab (one patient, 3 cycles).
Overall survival of patients with NLPHL is shown in
Fig. 1. Two-year survival was 96.0 %; five-year survival
was 94.0 %; and 10-year survival was 94 %. During follow-
up, five patients (6.8 %) died. Three patients died as a result of
NLPHL, and these all showed histologic transformation to
DLBCL with transformation to a T cell-/histiocyte-rich large
B cell lymphoma (T/HRBCL) in one of these patients. Two
patients died of other causes; the cause of death was unknown
for one patient, and the other patient died because of an infec-
tious complication after lower anterior resection for colorectal
cancer.
Ten-year overall survival was 96.8 % for stage I disease,
89.4 % for stage II disease, 91.7 % for stage III disease, and
100 % for stage IV disease. Five-year OS was similar to 10-
year OS. Progression-free survival was 78.6 % after 5 years
and 75.8 % after 10 years (Fig. 2). Fig. 2b shows progression-
free survival rates according to stage at presentation.
Six patients (8.2 %) had histologic transformation to
DLBCL, two of which were of T/HRBCL subtype. These
transformations all occurred in the first 5 years after diag-
nosis. Seven patients had a relapse of NLPHL after a
median of 26 months (range 21–74 months). Relapses
were mostly seen in patients with early stage disease,
and patients who were treated with radiotherapy alone
(n=6) and in only one patient who was treated with che-
motherapy (with 8 cycles of MOPP-ABV). None of the
patients in the watch-and-wait group (with or without sur-
gical excision) progressed.
Discussion
In this population-based study, we examined the epidemiolo-
gy, clinical features, treatment, and outcome of patients with
NLPHL in the Southeastern part of the Netherlands. We con-
firmed the diagnosis of NLPHL by central expert
hematopathological review, which caused exclusion of seven
patients (8.8 %) because of a discordant diagnosis. This is in
line with other studies which report discordance rates from 2.8
to 20 % [9, 15, 18]. As misclassification works in two direc-
tions, we cannot exclude that NLPHL patients have been clas-
sified as other malignant lymphomas (like cHL). We did not
re-review histology of all patients with a diagnosis of malig-
nant lymphoma over the same time period, so this could have
influenced Btrue^ incidence data.
Table 2 First-line treatment of
NLPHL patients according to
stage
Treatment
Stage (no/%) Watch-and-wait Radiotherapy Chemotherapy Combined modality
I (31/42.5 %) 7 (22.6) 20 (64.5) 3 (9.6) 1 (3.2)
II (24/32.9 %) 2 (8.3) 15 (62.5) 4 (16.7) 3 (12.5)
III (12/16.4 %) – 1 (8.3) 9 (75) 2 (16.7)
IV (5/6.8 %) – – 3 (60) 2 (40)
Unknown (1/1.4 %) – 1 (100) – –
Total (73/100 %) 9 (12.3) 37 (50.7) 19 (26) 8 (11)
Fig. 1 Overall survival in NLPHL patients is shown for all patients (a),
and broken-down according to stage (b); stage I (continuous line), stage II
(long-dotted line), stage III (short-dotted line), and stage IV (long- and
short-dotted line)
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During our study period, the incidence of NLPHL remark-
ably increased. This increase can be explained by several rea-
sons. First, better recognition of NLPHL due to the definition
of NLPHL as a distinct disease entity in the REAL classifica-
tion in 1994 may have caused part of the increase, since inci-
dence of total HL did not change during this period. Second,
technical improvement in immunohistochemistry and avail-
ability of this technique could have contributed to the rise in
incidence. Third, before 2000, recording of hematological ma-
lignancies from pathology or hematology labs possibly was
not always accurate.
NLPHL is a unique disease entity with other clinical fea-
tures than classic Hodgkin lymphoma [19]. Our study con-
firms the male predominance in NLPHL patients which was
evenmore striking than in previous reports. In line with earlier
studies, B symptoms were rare, and most patients presented in
an early disease stage. The EORTC and IPS (Hasenclever)
scores were recorded, but it has to be noted that these scores
have only been validated for cHL and not for NLPHL.
Patients were treated with radiotherapy (50.7 %), chemo-
therapy (26 %), combined modality (11 %), or careful follow-
up after removal of the lymph node (12.3 %). In other studies,
all these treatment modalities were also used, but with
different frequencies reflecting the lack of a standard treat-
ment. Because of the small number of patients in subgroups,
we were unable to perform statistical analyses on clinical
markers, therapy, or outcomes.
We did not observe disease progression in any of the pa-
tients with a watch-and-wait approach (with or without surgi-
cal excision). Together with recent studies [18], this indicates
that careful follow-up and treatment in case of progression can
be a good option in patients with early stage disease who have
only one affected lymph node that is completely removed by
diagnostic biopsy. Several new treatment modalities and ad-
justments to existing treatments have been proposed to make
treatment as little toxic as possible. Good short-term results
have been reported from the anti-CD20 antibody rituximab
[11] as monotherapy, but relapses occur frequently [20–22].
Possibly, a combination of rituximab and chemotherapy will
result in better long-term disease control. Very low-dose in-
volved-field radiotherapy, with a dose of 2 × 2 Gy as used in
indolent non-Hodgkin lymphoma, can be an effective alterna-
tive treatment in frail patients or in those with contraindica-
tions for more intense regimens [23]. A recent German study
showed similar results for combined modality treatment,
extended-field radiotherapy, and involved-field radiotherapy
in patients with stage IA NLPHL and concluded that
involved-field radiotherapy should be considered as standard
treatment because it carries the lowest risk of toxicity [22].
Seven patients (9.6 %) in our cohort had a relapse, which is
comparable to the 10 % relapse rate in a recent study from
Farrell et al. [9]. In the study with the highest numbers of
patients with a watch-and-wait strategy, 40 % relapsed within
a median follow-up of 9.5 years [18]. In the cohort where no
patients were on a watch-and-wait strategy, 23 % relapsed
within amedian follow-up of 11.3 years [24]. Histologic trans-
formation during the follow-up period occurred in six of our
patients (8.2 %), which is comparable to percentages given in
literature that range from 2.7 to 13 % [9, 15]. Transformation
to aggressive lymphoma can increase up to 30 % at 20 years
after initial diagnosis [15].
Five patients (6.8 %) died during follow-up, three due to
NLPHL, and two because of other causes. In the study of
Farrell, the overall survival was 100 % with a median
follow-up of 53 months [9]; the reported death rates in other
recent studies varied from 8.5 to 16.8 % [1].
In conclusion, the results from our study corroborate the
results of other recent studies and may serve to develop inter-
national joint strategies to optimize treatment for patients with
NLPHL. Only well-designed randomized intergroup trials can
provide results for developing the best treatment in a good
balance between efficacy and toxicity. Since we still found a
discordance rate of 8.8 %, we strongly recommend central
review by an expert hematopathologist in the initial diagnosis
as reported earlier in a cohort of patients with Hodgkin lym-
phoma in the Southeast of the Netherlands [25].
Fig. 2 Progression-free survival in NLPHL patients is shown for all
patients (a), and broken-down according to stage (b); stage I
(continuous line), stage II (long-dotted line), stage III (short-dotted line)
and stage IV (long- and short-dotted line)
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